Prosomatostatin (pro-S) and its bioactive posttranslational products, somatostatin-14 (S-14), somatostatin-13 (S-13), and somatostatin-28 (S-28), were measured in human plasma by the use of immunoglobulins to the NH2-terminus of S-28 conjugated with agarose to separate them and, thereafter, by RIA with an antiserum recognizing the COOH-terminus of pro-S, and by specific RIA for the NH2-terminus of S-14 and pro-S. In healthy men, mean basal levels of pro-S were 4 pg equivalent S-14/ml; S-14/S-13 combined were 9 pg equivalent S-14/ ml; and S-28 levels were 16 pg/ml. After a 700-kcal meal, pro-S, S-14, and S-14/S-13 did not change, whereas S-28 levels doubled by 120 min and remained elevated for 240 min. To evaluate the origins of these peptides, their levels were compared in peripheral, portal, gastric, and mesenteric veins of anesthetized patients and in patients with total resection of stomach and pancreas before and after nutrient intake. The stomach and small intestine were sources of both peptides; however, most S-28 originated in the small intestine. These findings suggest that, in contrast to S-14, S-28 is a hormone and may modulate postprandial nutrient absorption and use.
Introduction
The tetradecapeptide somatostatin (S-14)1 has stimulated much interest because it inhibits diverse metabolic functions (1) . Relevant to fuel homeostasis, S-14, in pharmacologic doses, decreases the secretion of several peptides from the gastrointestinal (GI) tract and pancreas and alters intestinal peristalsis (1, 2) . Because S-14 is secreted from cells that are widely distributed, notably in the central and peripheral nervous systems, pancreas, and GI tract (3) (4) (5) (6) , the prevailing belief is that it acts on adjacent cells to modulate the release of specific secretory products (7, 8) . On the other hand, somatostatin-like immunoreactivity (SLI) is present in mammalian plasma (9) (10) (11) (12) (13) , and rises after ingestion of nutrients or infusion of supraphysiologic doses of neurotransmitters and selected GI peptides (14) (15) (16) (17) (18) (19) . From immune neutralization studies in dogs and S- 14 infusions into man mimicking postprandial levels of SLI, Schusdziarra et al. (20) and Zyznar and colleagues (21) , postulated that circulating S-14 acts as a hormone that may be involved in nutrient assimilation.
SLI in human plasma is composed of a heterogeneous group of substances, including a protein of large molecular weight, termed "big plasma somatostatin," which is thought to be an immunoglobulin (22) , and three peptides cleaved from their precursor, prosomatostatin (pro-S). These include somatostatin-28 (S-28), a 28-amino acid-containing peptide incorporating S- 14 at its COOH-terminus, S-14, and des-Ala S-14(S-13) (23) . Because pro-S is processed to either S-28 or S-14 in different cells (24) (25) (26) , it is plausible that they fulfill divergent roles. Their precise measurement has been hindered by the use of nonspecific RIA directed to the central region of S-14, precluding their independent quantification in native plasma. S-28 can be separated from S-14 and S-13 by gel filtration and substances with similar elution profiles have been found in plasma of the rat, dog, man, and pig (27) (28) (29) (30) (31) . In- creased plasma levels of peptides coeluting with §-28 and S-14 in response to food intake in man have been reported (32, 33) . However, further understanding of the secretion and biologic roles of pro-S related peptides has been hampered by difficulties in carrying out repetitive gel filtration of small amounts of plasma and the use of nonspecific RIA. Therefore, we developed polyclonal antisera against different regions of pro-S and used the antibodies for selective immunoadsorption and RIA. In conjunction with an RIA specific for S-14, separation by gel filtration, and HPLC, these methods have enabled us to identify and measure pro-S and its COOH-terminal cleavage products and determine if they are differentially released after nutrient ingestion in men. To assess indirectly the major sources of circulating pro-S-derived peptides from the GI tract, we have quantified their basal and postprandial levels in patients with total gastrectomy and total pancreatectomy and in venous plasma from regions ofthe stomach and small intestine in man.
Methods
Peptides. Tyr'4-S-28 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , Tyr'-S-14, and Tyr"-S-14 were purchased from Peninsula Laboratories, San Carlos, CA. S-14, S-13, S-12, and analogues of S-14 in which alanine or tyrosine was substituted for residues at the 5, 6, 8, and 10 positions were gifts from Dr. J. Rivier, Salk Institute, La Jolla, CA. S-28 was donated by Dr. L. Pradayrol, Karolinska Institute, Stockholm, Sweden, and purchased from Peninsula Laboratories. S-28 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] , S-28[1-14J, and 13 analogues, in which the amino acids were sequentially deleted from the NH2-terminus of S-28, were kindly provided by Dr. N. Ling and Dr. R. Guillemin, Salk
Institute. Pro-S was partially purified from media from a propagated rat medullary cell carcinoma cell line (34) . The 13-amino acid NH2-terminal peptide of pro-S (pro-S-NTP) and Try'4-pro-S-NTP were custom synthesized at Peninsula Laboratories. The tyrosinated peptides (1-5 ug) were coupled with 1251 Na (Amersham Corp., Arlington Heights, IL) at pH 10 by a lactoperoxidase method (35) . The radiolabeled peptides were separately filtered through a 1 X 40 cm column of Sephadex G-25 (Fine) (Pharmacia Fine Chemicals, Uppsala, Sweden) equilibrated in 0.1 N acetic acid (HAc) containing 0.1% BSA (MilesPentex, Kanakakee, IL) at 15-20 ml/h. The column was calibrated with blue dextran with molecular mass of> 1 X 106 D and 3H20 (New England Nuclear, Boston, MA). The elution positions were described by the coefficient of distribution Kd = (Ve -V1)/V1. The radioactive peptides reacting optimally with the specific antisera were eluted with the following Kd: 1251-Tyr'4-S-28 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , Kd = 0.73; 125I-Tyr'-S-14 and 125I-Tyr' '-S-14, Kd = 1.10. The tracers were then diluted in appropriate buffers and stored at -20'C.
Antisera. Tyr"-S-14 and S-14 were separately linked to thyroglobulin (Tg) by dissolving 5 mg in 5 ml of sterile NaCl containing 20 mg bovine Tg and 920 mg carbodiimide (25) . The solutions were dialyzed and frozen at -20°C. Diazo compound was synthesized as follows: 18 mg of benzidine were dissolved in 0.4 ml warm HCl solution (2.4 ml 1 1.6 N HCI in 15 ml H20) and 0.1 ml of Na nitrite solution (69 mg in 0.5 ml H20) was added. After 5 min at 4°C, a saturated solution of sulfamic acid (60 Ml) was introduced resulting in 6 mg of diazo compound per 100 Ml. 5 mg ofTyr"-S-14 were coupled with tyrosines in 10 mg Tg dissolved in 1 ml of 130 mM NaCl in 160 mM Na borate buffer, pH 9, by addition of 15 Ml of diazo compound (0.8 mg) at 4°C for 2 h. The conjugates were extensively dialyzed in water and lyophilized. Based on distribution of free and bound '251-Tyr analogues, we calculated that 25-30% ofthe peptides were linked to Tg. Approximately 30 Mg of peptide was emulsified in CFA and injected intradermally at 10-20 sites into each of 10 young female New Zealand white rabbits. Boosters of the same preparations were given every 3 mo. The antisera were tested for titer, specificity, and avidity by measuring the binding of the different iodinated peptides by RIA. The following trivial designations were assigned to the antisera (AS) selected for RIA: F-4, which was obtained with Tyr'4-S-28 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) joined with Tg by carbodiimide; AS-77, which was made with Tyr"-S-14 coupled to Tg by diazotization; AS-1O, which was generated by linking S-14 to Tg with carbodiimide; and Kiisha, which was obtained by conjugation of Tyr'4-pro-S-NTP to limpet hemocyanin with carbodiimide (34) .
RIA. The optimal conditions for equilibrium binding of the radioligands with their respective antisera were (a) F-4, AS-77, and Kiisha: 50 mM barbital buffer, pH 8.0; (b) AS-10: 130 mM borate buffer, pH 8.5. Each buffer contained 0.25% BSA and thiomerosal (1:10,000 final concentration). Assays were carried out by mixing 0.9 ml buffer with 0.05 ml of diluted antiserum to achieve final concentrations of 1:8,000 for F-4, 1:60,000 for Kiisha, 1:4,000 for AS-77, and 1:100,000 for AS-10. Statistical analysis. Data were analyzed by the t test, using a statistical program on CLINFO, and P values < 0.05 were considered significant.
Results
Characterization of antisera against regions ofpro-S. The binding characteristics of F-4 antiserum with S-28 and peptides with amino acid deletions from the NH2-terminus of S-28 are shown in Fig. 1 A. This antiserum interacted not only with S-28(1-14) but also recognized S-28, S-27, S-26, and S-25 with equal avidity. S-24 reacted less well and all other peptides did not interact with this antiserum. These findings were confirmed by their behavior when filtered through a column of agarose-F-4 conjugate. S-28 and analogues through S-24 were retained, whereas S-23 and peptides with further NH2-terminal deletions and pro-S traversed the immunoadsorbent unhindered. Therefore, we infer that the epitope with which this antiserum reacted involved the Asn5-Pro6 sequence of S-28. Of note, the cross-reactivity ofthis antiserum with S-28(1-12) was extremely poor, and pro-S did not bind, implying that modifications of their secondary structure also affected binding. The lowest limit of detection of S-28 with F-4 was 2 fmol per tube, with interassay and intraassay variances of 15 (n = 10) and 8% (n = 10), respectively. In Fig. 1 B are displayed the specificities of antiserum AS-77 obtained by orienting the S-14 molecule towards its NH2-terminus by Tyr-diazo-Tyr linkage at position 11. From displacement curves with the various peptides, Ala' and Gly2 appear to be the critical determinants. Based on the sensitivity of the displacement curves and the lack of binding of pro-S, S-28, and other analogues to bind with this antiserum at other than inordinately high concentrations, for practical purposes in measurement, AS-77 was considered specific for S-14. The minimum of S-14 detected with AS-77 was 2 fmol per tube, with interassay and intraassay variances of 10 (n = 10) and 8% (n = 10), respectively. The interactions of S-28, related peptides, and analogues with antiserum AS-10 are shown in Fig. 1 C. This immune serum was judged to interact with the Phe7-Trp8-Lys9 residues of S-14. Because it bound peptides in the COOH-terminal region of pro-S including S-28, AS-10 is not specific for S-14. From stoichiometric comparisons, S-13, S-12, and S-14 interacted equivalently, whereas, S-28 had only one-third of the avidity of S-14, from which we infer that the structural configuration imparted by the NH2-terminal amino acids in SS-28 partially occluded ligand-antibody interactions.
The minimum reliable threshholds for detection of S-14 and S-28 with AS-IO were 1 fmol (2 pg) per tube and 1 fmol (3 pg) per tube, respectively, with interassay and intraassay variances of 8 (n = 10) and 6% (n = 10) for each. The characteristics of the assay for pro-S-NTP and its reactivity with pro-S have been previously reported (34) .
Characterization ofpro-S-relatedpeptides in plasma. After acidified plasma samples were processed through Sep-Pak, the peptides were measured either directly by AS-10 and AS-77 RIA or after their separation by region specific immunoadsorbents and gel filtration (see Methods). Because F-4 antiserum interacted only with peptides from S-28 to S-24, it was coupled to agarose to separate S-28 from S-14 and S-13. Recoveries of authentic S-14 and S-13 added to buffer or acidified plasma, processed through SepPak and passed freely through the immunoadsorbent (fraction 1) were 80±3% (n = 10), whereas, S-28 through S-24, which were retained by the immunoadsorbent and eluted with 0.2 N HAc plus 0.2% BSA (fraction 2), were recovered with an efficiency of 50±5% (n = 10). Therefore, values in both fractions 1 and 2 were corrected to 100%.
To determine if the endogenous peptides separated by this technique corresponded with pro-S and its processed peptides, (Fig. 2 A) . The identity of the -front-running peak eluted at V. has not been established;
however, partially purified pro-S from the media of a cultured rat medullary thyroid carcinoma cells coeluted with this peak. The peptide in this eluate also registered in the Pro-S-NTP RIA, and all the immunoreactivity was retained on the AS-1O immunoadsorbent indicating that this peak contained pro-S. Lacking purified pro-S for comparison of avidity for AS-10 antiserum, we could not precisely compare the magnitude of the V. peak with the other two peaks, which were quantified with S-28-and S-14 as standards. With S-14 as standard, it composed one-eighth of the total peptides, and approximated 20% of the peak coeluting with S-14/S-13. The immunoreactivity in the remaining peaks coincided with the Kd of authentic S-28 and S-14/S-13, respectively. In Fig. 2 Peptides from plasma (50 ml) were adsorbed and eluted from SepPak and subjected to Biogel P-l0 chromatography. Peak 1 was segregated, concentrated, and analyzed by AS-lO RIA (n = 6). (C) Peptides from plasma (50 ml) were adsorbed and eluted from SepPak and subjected to Biogel P-10 chromatography. Peak 3 (Fig. 2 C) was segregated, concentrated, and analyzed by AS-1O RAI (n = 11). (D) Blood (50 ml) was collected directly into 500 mM Na2 HPO4, final pH 5.2, the red cells separated, the pH adjusted to 3 and peptides from plasma were adsorbed, eluted from SepPak, and analyzed by AS-77 RIA (n = 15). (E) Peptides from plasma (5 ml) were adsorbed and eluted from SepPak and measured in fraction 2 from the F-4 immunoadsorbent by AS-1O RIA (n = 34). BSA, was lyophilized, concentrated by SepPak, and applied to C-18 reverse-phase column with a 5-90% CH3CN/0. 1% TFA linear gradient. The eluates were analyzed by AS-1O RIA. Arrows refer to retention times of authentic standards. separation offraction 2 by F-4 immunoadsorption the fraction underwent HPLC. As shown in Fig. 3 , a minor (< 5%) and major peak measured by AS-10 RIA were found. The latter had a retention time coincident with that of authentic S-28.
Basal levels of pro-S-derived peptides in man. Levels of pro-S and related peptides, in combination and after separation from each other, were obtained in plasma of healthy young men after an overnight fast. The mean basal level ofthe combiied peptides in plasma after separation of big plasma somatostatin by means of SepPak and analysis by AS-1O RIA was 15±0.8 (SE) pg equivalent S-14/ml (n = 35). In Fig. 4 are shown the mean and range of values for the peptides using different methods for their separation. In Fig. 4 A are recorded the combined levels of peptides in fraction 1 from the F-4 immunoadsorbent. Mean values of 12 pg equivalent S-14/ml include pro-S, S-14, and S-13. To measure their separate contributions, plasma was passed through SepPak, the retained peptides eluted, filtered through Biogel P-10 and peaks 1 and 3 corresponding to pro-S and S-14/S-13, respectively, were segregated, concentrated by SepPak and assayed by AS-10 RIA. (Recoveries of standards were 72±5% and unknowns were appropriately corrected.) Mean levels for pro-S were 4 pg equiva-1584 Ensinck, Laschansky, Vogel, Simonowitz, Roos, and Francis I lent S-14/ml (Fig. 4 B) and S-14 and S-13 together were 9 pg equivalent S-14/ml (Fig. 4 C) . To separately measure S-14 we used AS-77 RIA, which discriminates between S-14 and S-13. Aminopeptidase mediated cleavage of NH2-terminal alanine of S-14 during plasma collection and processing was minimized by aspirating blood into chilled syringes containing 500 mM Na2HPO4 to achieve a final pH of 5.2, removing the red cells, and adjusting plasma to pH of 3. The peptides were then separated from plasma enzymes by SepPak and assayed (Fig. 4  D) . The mean value of 2 pg S-14/ml was significantly lower (P < 0.005) than the mean level of 9 pg equivalent S-14/ml for S-14/S-13 combined in peak 3 by gel filtration. Thus, we interpret these differences as reflecting the contribution of S-13 in this peak. In Fig. 4 E is displayed the range of S-28 values separated in fraction 2 by the F-4 immunoadsorbent. The mean level was 16 pg/ml measured by AS-10 RIA using S-28 as standard. Of note, the mean basal levels of 12 pg equivalent S-14/ml for fraction 1 together with the 16 pg equivalent S-28/ml in fraction 2 exceed the mean of 15 pg equivalent S-14/ml in nonfractionated plasma. This apparent discrepancy is due to the lack of stoichiometry in interaction of these peptides with AS-IO antiserum. Because S-28 is only one-third as avid as S-14 in displacement, the values for S-28 require division by three to correct for its contributior ated plasma.
Plasma levels ofpro-S-derivedpeptides afti Figure 6 . Levels of S-28 in plasma before and after intake of a liquid meal (Ensure Plus, 700 kcal). Peptides from plasma (5 ml) were adsorbed and eluted from SepPak and measured in fraction 2 from the F-4 immunoadsorbent by AS-IO RIA.
n in nonfractionmeal of mixed composition. Mean basal levels of pro-S, S-14 and S-13 in fraction 1 from the F-4 immunoadsorbent in 18 erfood intake. In subjects were 14 pg equivalent S-14/ml and did not change id S-14/S-13 in throughout 4 h after food intake (Fig. 5 A) . In five individuals stion of a liquid studied separately, S-14 levels, quantified by AS-77 RIA after processing blood collected in 500 mM Na2HPO4, pH 5.2, were also unaltered after food intake (Fig. 5 B) . Levels Table I . Concentrations of peptides in fraction 1 43 In Fig. 7 are displayed the values for the various peptides in peripheral plasma from patients in whom the stomach or pancreas or both had been resected. Basal levels of pro-S, S-14/S-13 (fraction 1) were similar to those found in normal individuals (Fig. 4 A) . In the two patients with total gastrectomy, there was a small rise in these peptides by 30 min, whereas in the patient with the total gastrectomy and pancreatectomy and the patient with total pancreatectomy, no increase was seen. In all three patients whose stomach had been removed, basal levels of S-28 in fraction 2 were at the upper range or exceeded those seen in healthy men (Fig. 3 E) . After food intake, there was a twofold increase in S-28 within 30-60 min with a relatively rapid decline in the ensuing 120 min. In the patient with a total pancreatectomy, S-28 levels were elevated from baseline by 60 min (P < 0.001), which persisted throughout the following 3 h. The rapid delivery of nutrient to the small intestine in the patients with total gastrectomy was confirmed by markedly increased glucose and insulin levels that peaked within min after food intake.
lower than the published values measured as total pro-S related peptides in intact plasma or after their separation by gel filtration. Levels of peptides either in fraction 1 from the F-4 immunoadsorbent or coincident with the peak of authentic S-14 on gel filtration were significantly greater than the values obtained by RIA, suggesting that the residual peptide coeluting with S-14 corresponds to S-13. Under the conditions used in our HPLC, we were unable to separate S-14 from S- 13 and found only a single peak in fraction 1 from the F-4 immunoadsorbent that coincided with S-14/S-13. Less than 10% of the peak by AS-10 RIA was recorded in the AS-77 RIA.
Because we collected blood under conditions minimizing the rapid in vitro hydrolysis of the Ala' of S-14 by plasma aminopeptidases (37), we contend that, in our subjects, S-13 accounted for up to 80% of the circulating component usually attributed to S-14. It is also possible, but not yet established, that the Gly2 of S-14 is removed resulting in S-12. We have found that S-14 is released intact from D cells within monolayer cultures of the rat islet (unpublished results); hence, if this peptide is also secreted as such from all somatostatin containing cells in man, it seems likely that the NH2-terminal alanine is deleted during the translocation of S-14 across capillary endothelial cells or while traversing organs such as the liver or lung. In this context, Sacks et al. (38) , and Ruggere and Patel (39) have shown that the S-14 is rapidly converted to S-13 by the rat liver. The latter investigators have also found that, when perfused through rat liver and lung, S-28 is cleaved sequentially at its NH2-terminus leading to S-25 and eventually to S-14 (39, 40 S-14 is the major circulating peptide (1, 15, 19, 21 Figure 7 . Levels of pro-S-derived peptides in plasma with total gastrectomy (gast) and/or pancreatectomy (px) before and after the ingestion of a liquid meal (Ensure Plus, 700 kcal). Peptides corresponding to pro-S, S-14/S-13, and S-28 were measured in fractions 1 and 2 from the F-4 immunoadsorbent by AS-10 RIA as described in legends to Figs. 5 A and 6, respectively.
HPLC that S-25, retained by the F-4 immunoadsorbent, was present in human plasma. Moreover, because S-14 did not change after food intake despite increases in S-28, the liver would not appear to be a major source of S-14 through transformation of S-28.
In the basal state, we found that S-28 levels were fourfold greater than those of S-14/S-13. In the dog and man, the t112 of S-14 ranged between 0.6 and 1.7 min and that for S-28 was 2.8 min (41), which we have confirmed in man (unpublished results). Therefore, when differences in clearance is taken into account, under steady state conditions, the amounts of S-14/ S-13 and S-28 delivered into the circulation are probably roughly equivalent.
After food intake in dog and man, increases in SLI have been repeatedly observed (15, (17) (18) (19) . Few studies, however, have resolved SLI into its components. Using gel filtration, Schusdziarra et al. (15) and Dunning and Taborsky (42) , reported that only S-14 increased after feeding dogs a meal of liver in 1 N HCL. Because canine plasma contains S-28 (29) , and in our hands, only S-28 increased in dogs fed Ensure (unpublished results), it is possible that acidified liver extract may have led to gastric retention and release of S-14 from the stomach. In man, both S-28 and S-14 have been reported to rise after intake of a mixed meal with most of the increase attributed to S-28 (23, 29, 30) . In this study, we have confirmed the rise in S-28 but we were unable to detect any significant changes in S-14/S-13. Although we cannot readily explain these divergent findings, in none of the published reports was there evidence of protection against the actions of aminopeptides, therefore, conversion of S-28 to smaller molecular weight species coinciding with S-14/S-13 by gel filtration may have occurred. It is of interest that pro-S also did not increase after food intake. Because it is plausible that it is cosecreted with S-28, the lack of a perceptible increase may be due to our inability to precisely quantify it lacking a purified standard. Alternatively, increases in the circulating pool from cells in which S-28 was processed may have been obscured by the contribution of pro-S from those cells in which S-14 was generated and unaffected by ingested nutrient.
It is generally agreed that most of the circulating pro-S-related peptides originate in the gastro-entero-pancreatic organs (1, 2) . However, the pancreas contributes less than do either stomach or intestine (43, 44) and as the amount of S-28 in rat pancreas and canine stomach are small and unlikely to be intermediates in the processing to S-14 (24, 26) , it is probable that neither of these organs are major sources of circulating S-28. This is in keeping with our findings in pancreatectomized patients in whom levels of S-28 and S-14/S-13 were similar to those of normal men during basal and postprandial phases. In this study, S-28 and S-14/S-13 were released from both the stomach and small intestine. Our inability to measure regional blood flow in man does not permit definite conclusions as to the relative amounts ofeach peptide delivered to the hepatic portal venous drainage. Nonetheless, estimates can be derived from blood flow measurements from various visceral organs in the baboon, which is similar to man. In these animals, the resting blood flow from the small intestine is six-to sevenfold greater than from the stomach (45) . Therefore, even though the static measurements of S-28 were the same and, in the case of the S-14/S-13, higher in the veins from the stomach, it is plausible that, during the basal state, most of these peptides originated from cells within the small intestine. The early onset and twofold rise in S-28 levels in patients with total gastrectomy, comparable to the changes over a longer period in normal subjects, imply that the stomach contributes little to the postprandial increase in S-28. These observations thus provide additional support to in vitro data suggesting that S-28 is the terminal peptide processed from pro-S in epithelial cells ofthe small intestine, whereas S-14 is the final product in most gastric D cells and gastrointestinal neurons (25) .
Our findings that S-28 but not S-14 levels are increased after nutrient intake raises the possibility that they serve divergent functions. There is considerable evidence for a paracrine role for S-14 (1, 7, 8) . The presence of S-14/S-13 in blood may reflect their spillover from multiple sources rather than the assumption that they are hormones. In contrast, it is reasonable to postulate that S-28 might act on such distant targets as the B cells in the endocrine pancreas. Bonner-Weir and Orci (46) have shown that the central mass of B cells in the islet is perfused centrifugally, thereby making it unlikely that S-14 released from D cells within the mantle could have access to the B cell core. Recently, Samols and Stagner concluded that the cellular sequence of perfusion is from B to A to D cells (47) . Combined with our inability to demonstrate postprandial changes in S-14, these findings thus, do not support a primary regulatory role for this peptide on insulin secretion. The notion that S-28 might modulate insulin release is supported by studies indicating that it is not only more potent than S-14 in inhibiting insulin release (48) but is bound to B cells with a higher affinity (49, 50) . Proof of a physiologic action for circulating S-14/S-13 or S-28 has been indirect. Infusions of S-14 in man to attain steady-state levels approximating post-prandial increments of SLI result in suppression of several peptides from the pancreas and GI tract (21) . Nonetheless, because we have been unable to document a significant change in S-14/S-13 after eating, we contend that such studies are not relevant. By comparison, S-28 infusions have led to inordinately high concentrations and their effects cannot be equated with physiologically appropriate postcibal levels (5 1). Schusdziarra et al. (20) postulated that the S-14 might play a role in nutrient homeostasis based on enhanced levels of several peptide hormones including insulin in dogs after infusion of antisomatostatin serum. Although they believed that these perturbations reflected removal of circulating S-14/S-13, it is also possible that they were due to neutralization of S-28 levels. To our knowledge, this question has not been resolved by infusion of immunoglobulins against S-28.
In summary, these studies have shown that S-28, but not S-14/S-13, is increased in the peripheral blood of man after ingestion of a mixed nutrient meal. The selective rise in S-28 during food intake from intestinal endocrine cells, implies that this peptide acts as a hormone that may modulate several functions involved in nutrient absorption and assimilation.
